Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET

Next Previous
Trial Profile

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cixutumumab (Primary)
  • Indications Ewing's sarcoma; Leiomyosarcoma; Neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma
  • Focus Therapeutic Use
  • Sponsors ImClone Systems

Most Recent Events

  • 08 May 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
  • 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 10 Mar 2012 This trial has been recruiting in Belgium, Germany, Netherlands and France and completed in Spain as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top